Search Results

Locanabio, Inc. today announced that Jim Burns, Ph.D., Locanabio’s chief executive officer, will provide a corporate overview at 5:30 pm. ET on Monday, October 2nd at Chardan’s 7th Annual Genetic Medicines Conference which is being held in New York City.

Locanabio, Inc. today announced the presentation of data demonstrating the packaging and delivery of its proprietary small nuclear RNA (snRNA) platform using adeno-associated virus (AAV).

Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, announced that CureDuchenne Ventures, the strategic investment arm of CureDuchenne, has made an equity investment in Locanabio.

Locanabio, Inc. today announced that data from LBIO-115, its vectorized snRNA exon skipping program in development for the treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, and its Cas13d-mediated program for C9orf72-related amyotrophic lateral sclerosis (ALS) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

Locanabio, Inc. announced the presentation of data from its lead vectorized snRNA exon skipping program, LBIO-115, in development for the treatment of Duchenne muscular dystrophy.

Locanabio, Inc. announced the first presentation of data from its next generation engineered small nuclear RNA, or snRNA, platform, which is designed to efficiently deliver targeted snRNA payloads via an adeno-associated virus for long-term therapeutic expression.

Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, announced that its leadership team will participate in the following upcoming investor conferences.

Locanabio, Inc. today announced the appointment of Kat Lange as chief financial officer.